La Jolla Pharmaceutical Company announced that George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, has left the Company to pursue other interests. A search for a new Chief Executive Officer has been initiated. In the interim, a committee of the Board, comprised of Kevin Tang and Craig Johnson, will provide Board-level oversight of the Company's management team.
La Jolla Pharmaceutical Company
Equities
LJPC
US5034596040
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+21.25% | 127B | |
+24.13% | 117B | |
+26.26% | 27.67B | |
-18.91% | 20.33B | |
-15.87% | 16.79B | |
-17.94% | 15.63B | |
+13.57% | 14.84B | |
-47.70% | 14.65B | |
+57.97% | 14.43B |